Biotechnology company XBiotech has reported positive data from its Phase II trial of MABp1 to treat acne vulgaris.
The open label study, which evaluated True Human monoclonal antibody MABp1 in patients with moderate-to-severe disease, demonstrated persistent improvement in lesions throughout the therapy, with up to 42% reduction in eight weeks.
XBiotech president and CEO John Simard said True Human monoclonal antibody therapy has the potential to provide a new biologic approach to acne management.
"The safety of our technology - which has been well established with 145 patients receiving over 450 doses of MABp1 - allows us to focus on a variety of indications, including those that are non-life threatening such as acne," Simard said.
"As with other conditions involving chronic inflammation, IL-1a plays a significant role in the acne disease process and neutralising its effects with MABp1 shows highly promising early results.
"The opportunity to address a common, yet challenging, skin condition with a novel biological drug represents a significant development in dermatological care."
The Phase II multicentre study involved XBiotech proprietary platform technology.
MABp1 has demonstrated a significant safety profile across multiple therapeutic indications, and positive interim results from the trial form the basis to advance the development of the first biologic therapy targeting the inflammatory cytokine IL-1a for acne treatment.